Can suzetrigine reduce opioid use after surgery?

Can suzetrigine reduce opioid use after surgery?

Suzetrigine (Journavx) gives clinicians a way to treat acute pain by blocking NaV1.8, a sodium channel involved in pain signals in peripheral nerves. The US FDA approved it in January 2025 for adults with moderate to severe acute pain. A study in the November 2026 issue of JAMA Otolaryngology raises a more specific question. Does adding it to a postoperative regimen reduce how much opioid a patient needs? [1][3]

What the randomized trials established

Two blinded trials enrolled 1,118 adults after abdominoplasty and 1,073 after bunion surgery. Patients received suzetrigine, hydrocodone with acetaminophen, or placebo. All three groups could request rescue ibuprofen. Investigators combined repeated pain ratings into a measure of relief across 48 hours, called SPID48. Higher values mean more cumulative relief. [2]

Suzetrigine exceeded placebo by 48.4 point-hours after abdominoplasty and 29.3 after bunion surgery. Dividing by 48 gives an average advantage of about 1.0 and 0.6 points, respectively, on the 0–10 pain scale across the observation period. Neither trial demonstrated superiority to hydrocodone with acetaminophen. The bunion surgery comparison favored the opioid combination. The trials were designed to test superiority, so a claim of equal efficacy would also go beyond their results. [2][4]

What the head and neck surgery study adds

At one hospital, researchers reviewed 146 patients after free-flap reconstruction or transoral robotic surgery. Of these, 41 received suzetrigine alongside multimodal analgesia. After adjustment, the estimated median difference in total inpatient opioid consumption was 76.4 morphine milligram equivalents lower (95% confidence interval, 13.9 to 138.8 lower), with similar recorded pain scores. Treatment allocation was nonrandom, so other differences between patients could explain part of the association. [3]

What to check before use

The US label contraindicates combining suzetrigine with strong CYP3A inhibitors and advises avoiding it in severe hepatic impairment. Reported reactions include itching, muscle spasms, rash and elevated creatine phosphokinase. Use for acute pain beyond 14 days has not been studied. Egyptian registration and availability require separate local verification. [1][4]

What to take into practice

The evidence supports short-term postoperative analgesia. Whether routinely adding suzetrigine reduces opioid requirements across operations still needs randomized testing. [2][3]

Sources

Evidence checked on 21 November 2026.

[1] US FDA. Approval of suzetrigine for acute pain in adults (2025-01-30).

[2] Bertoch T et al. Two phase 3 randomized trials of suzetrigine. Anesthesiology (online publication) (2025-03-21).

[3] Bestourous DE et al. Suzetrigine after head and neck surgery. JAMA Otolaryngology–Head & Neck Surgery (issue date) (2026-11-01).

[4] DailyMed. JOURNAVX prescribing information, manufacturer label record updated October 2026 (2026-10-02).

Leave a Reply

Your email address will not be published. Required fields are makes.

Select your currency
USD United States (US) dollar